Long-Term Complete Remission of a Patient With Double-Hit Diffuse Large B-Cell Lymphoma Treated by Chemoimmunotherapy and Chinese Herbal Medicine

被引:2
|
作者
Liang, Henry [1 ,4 ]
Guo, Jessica [2 ]
Li, Chun Guang [3 ]
机构
[1] Western Sydney Univ, Campbelltown Campus, Artarmon, NSW, Australia
[2] Dr Henry Liang Clin, Artarmon, NSW, Australia
[3] Western Sydney Univ, NICM Hlth Res Inst, Penrith, NSW, Australia
[4] Dr Henry Liang Clin, Level 1, 66 Hampden Rd, Artarmon, NSW 2064, Australia
关键词
diffuse large B-cell lymphoma; double-hit lymphoma; complete remission; long term survival; Chinese herbal medicine; MULTICENTER;
D O I
10.1177/15347354221147515
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Double-hit diffuse large B-cell lymphoma (DHL) is an uncommon subtype of lymphoma which poorly responds to current drug therapies and has low rates of long-term survival in the patients. Herein, we report a case of a 73-year-old Caucasian male who was diagnosed with DHL with double-hit mutations of rearrangement of both c-MYC and BCL2 in November 2013. He commenced the standard R-CHOP-14 chemotherapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone) but changed to dose-adjusted DA-EPOCH-R protocol (etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone, and rituximab) in the second and third cycles due to double-hit mutation. Because of intolerance to the intensive therapy, the patient decided to switch to Chinese medicine intervention. From March 2014 to December 2019, he was prescribed with a classical Chinese herbal formula-Sijunzi Decoction plus Prunella vulgaris based prescriptions. After 2 months of the Chinese herbal medicine intervention, the patient felt his right groin mass disappeared. Imaging follow-up showed no residual masses, and no lymphadenopathy was seen. During the period of Chinese herbal medicine treatment, his adherence and tolerability were well maintained with no adverse events. Imaging surveillances afterward found no evidence of lymphoma recurrence. His regular blood tests indicated that the patient's blood counts were normal and stable; no hematologic toxicity, hepatoxicity, or nephrotoxicity associated with Chinese herbal medicine were found. Follow-up visits until 2020 found that he had been living and enjoying a good quality of life for over 8 years post-diagnosis. This case study illustrates the potential values of Chinese herbal medicine in DHL treatment, alongside chemo-immunotherapy, and in maintaining long-term survival and satisfactory quality of life for DHL patients. The case report provides clinicians with preliminary evidence of the use of Chinese herbal medicine as a therapeutic strategy in the management of DHL.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] The Impact of MYC Rearrangements and "Double Hit" Abnormalities in Diffuse Large B-Cell Lymphoma
    Lin, Pei
    Medeiros, L. Jeffrey
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2013, 8 (03) : 243 - 252
  • [22] A Rare Case of Double Hit Primary Hepatic Diffuse Large B-cell Lymphoma
    Saleem, Bilal
    Kassab, Ihab
    Mehta, Meetal
    Abia, David
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S1198 - S1199
  • [23] The Impact of MYC Rearrangements and “Double Hit” Abnormalities in Diffuse Large B-Cell Lymphoma
    Pei Lin
    L. Jeffrey Medeiros
    Current Hematologic Malignancy Reports, 2013, 8 : 243 - 252
  • [24] Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma
    Jaeger, Ulrich
    Tam, Constantine S.
    Borchmann, Peter
    McGuirk, Joseph P.
    Johansen, Marianne
    Waller, Edmund K.
    Jaglowski, Samantha
    Andreadis, Charalambos
    Foley, Stephen R.
    Westin, Jason R.
    Fleury, Isabelle
    Ho, P. Joy
    Mielke, Stephan
    Teshima, Takanori
    Salles, Gilles
    Schuster, Stephen J.
    He, Fiona
    Maziarz, Richard T.
    Mayer, Sebastian
    Makita, Shinichi
    Kersten, Marie J.
    Ghosh, Monalisa
    Wagner-Johnston, Nina
    Kato, Koji
    Corradini, Paolo
    Goto, Hideki
    Colicino, Silvia
    Agarwal, Abhijit
    Lobetti-Bodoni, Chiara
    Bishop, Michael R.
    BLOOD ADVANCES, 2022, 6 (16) : 4816 - 4820
  • [25] Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
    Green, Tina Marie
    Young, Ken H.
    Visco, Carlo
    Xu-Monette, Zijun Y.
    Orazi, Attilio
    Go, Ronald S.
    Nielsen, Ole
    Gadeberg, Ole V.
    Mourits-Andersen, Torben
    Frederiksen, Mikael
    Pedersen, Lars Moller
    Moller, Michael Boe
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (28) : 3460 - 3467
  • [26] Complete Remission and Long-term Survival of a Patient with a Diffuse Large B-cell Lymphoma Under Viscum album Extracts After Resistance to R-CHOP: A Case Report
    Gutsch, Johannes
    Werthmann, Paul G.
    Rosenwald, Andreas
    Kienle, Gunver S.
    ANTICANCER RESEARCH, 2018, 38 (09) : 5363 - 5369
  • [27] Long-term spontaneous regression of Stage IV diffuse large B-cell lymphoma
    Furukawa, Yoshiki
    Ando, Jun
    Ando, Miki
    Kinoshita, Shintaro
    Edahiro, Yoko
    Furuta, Takuya
    Ohshima, Koichi
    Komatsu, Norio
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2021, 61 (03) : 168 - 172
  • [28] Validation of the Double-Hit Gene Expression Signature (DLBCL90) in an Independent Cohort Diffuse Large B-cell Lymphoma of Germinal Center B-cell Origin
    Ha Nguyen
    Xu, Minlin
    Perry, Anamarija
    Skrabek, Pamela
    Nasr, Michel
    Bedell, Victoria
    Murata-Collins, Joyce
    Herrera, Alex
    Chan, Wing Chung
    Weisenburger, Dennis
    Scott, David
    Song, Joo
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 1355 - 1355
  • [29] Pleural fluid overload-associated large B-cell lymphoma with a formerly double-hit genotype
    Liaskas, Athanasios
    Xanthapeulos, Vasileios
    Arapaki, Maria
    Vassilakopoulos, Theodoros P.
    LANCET HAEMATOLOGY, 2023, 10 (04): : E306 - E306
  • [30] Validation of the Double-Hit Gene Expression Signature (DLBCL90) in an Independent Cohort Diffuse Large B-cell Lymphoma of Germinal Center B-cell Origin
    Ha Nguyen
    Xu, Minlin
    Perry, Anamarija
    Skrabek, Pamela
    Nasr, Michel
    Bedell, Victoria
    Murata-Collins, Joyce
    Herrera, Alex
    Chan, Wing Chung
    Weisenburger, Dennis
    Scott, David
    Song, Joo
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1355 - 1355